AU4954199A - Method for enhancing stable cellular creatine concentration - Google Patents

Method for enhancing stable cellular creatine concentration Download PDF

Info

Publication number
AU4954199A
AU4954199A AU49541/99A AU4954199A AU4954199A AU 4954199 A AU4954199 A AU 4954199A AU 49541/99 A AU49541/99 A AU 49541/99A AU 4954199 A AU4954199 A AU 4954199A AU 4954199 A AU4954199 A AU 4954199A
Authority
AU
Australia
Prior art keywords
creatine
combination
effervescent
amount
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU49541/99A
Other languages
English (en)
Inventor
Joseph W. Carnazzo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fortress Systems LLC
Original Assignee
Fortress Systems LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fortress Systems LLC filed Critical Fortress Systems LLC
Priority claimed from PCT/US1999/012597 external-priority patent/WO2000074647A1/en
Publication of AU4954199A publication Critical patent/AU4954199A/en
Abandoned legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU49541/99A 1999-06-07 1999-06-07 Method for enhancing stable cellular creatine concentration Abandoned AU4954199A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/012597 WO2000074647A1 (en) 1997-03-31 1999-06-07 Method for enhancing stable cellular creatine concentration

Publications (1)

Publication Number Publication Date
AU4954199A true AU4954199A (en) 2000-12-28

Family

ID=22272903

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49541/99A Abandoned AU4954199A (en) 1999-06-07 1999-06-07 Method for enhancing stable cellular creatine concentration

Country Status (3)

Country Link
EP (1) EP1187600A1 (cg-RX-API-DMAC7.html)
JP (1) JP2003501374A (cg-RX-API-DMAC7.html)
AU (1) AU4954199A (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200538738A (en) 2004-02-20 2005-12-01 Univ California Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
WO2013036885A1 (en) 2011-09-08 2013-03-14 The Regents Of The University Of California Metabolic flux measurement, imaging and microscopy
EP3435088A1 (en) * 2011-12-07 2019-01-30 GlaxoSmithKline LLC Methods for determining total body skeletal muscle mass

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19537494C2 (de) * 1995-09-25 1997-10-02 Desitin Arzneimittel Gmbh Kreatin zum Schutz von neuralem Gewebe

Also Published As

Publication number Publication date
JP2003501374A (ja) 2003-01-14
EP1187600A1 (en) 2002-03-20

Similar Documents

Publication Publication Date Title
US5925378A (en) Method for enhancing delivery and uniformity of concentration of cellular creatine
AU733474B2 (en) Improvements in or relating to compositions containing creatine
Matthews et al. Splanchnic bed utilization of glutamine and glutamic acid in humans
AU685565B2 (en) Creatine beverage and producing process thereof
US4725427A (en) Effervescent vitamin-mineral granule preparation
ES2286238T3 (es) Composicion para rehidratacion.
AP841A (en) Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection.
MX2014001746A (es) Metodo de produccion de niveles fisiologicos y terapeuticos de oxido nitrico por medio de un sistema de suministro oral.
JPH04112825A (ja) 脂質代謝調節剤
US8435570B1 (en) Nitrite formulations and their use as nitric oxide prodrugs
WO1999043312A1 (en) Aqueous creatine solution and process of producing a stable, bioavailable aqueous creatine solution
JP4811576B2 (ja) 水分電解質補給飲料
KR0143232B1 (ko) 철 공급용 제제, 비타민 공급용 제제 및 발포 제제의 안정화 방법
US20020131987A1 (en) Method for enhancing stable cellular creatine concentration
CN104382891A (zh) 通过施用肌酸化合物的透析患者中的细胞保护
Oestreicher et al. Influence of intraluminal constituents on zinc absorption by isolated, vascularly perfused rat intestine
EP1187600A1 (en) Method for enhancing stable cellular creatine concentration
JPH09183732A (ja) カリウムが支配的な非液系丸剤およびそれを用いた健康増進方法
ZA200110072B (en) Method for enhancing stable cellular creatine concentration.
US20040048925A1 (en) Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040133040A1 (en) Creatine salts and method of making same
US20040220266A1 (en) Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20090155442A1 (en) Method for enhancing delivery and uniformity of concentration of dietary ingredients
WO2009076742A1 (en) Effervescent dietary composition for enhancing delivery of dietary ingredients
Novotny et al. Molybdenum kinetics in men differ during molybdenum depletion and repletion